VR to Reduce Pain and Anxiety During GU Scans

Sponsor
Children's Hospital Los Angeles (Other)
Overall Status
Unknown status
CT.gov ID
NCT04251988
Collaborator
National Association of Theater Owners (Other)
410
2
2
22.5
205
9.1

Study Details

Study Description

Brief Summary

This study aims to test the effectiveness of virtual reality (VR) in reducing pain and anxiety in children undergoing voiding cystourethrograms (VCUG) at CHLA. A voiding cystourethrogram is a genitourinary diagnostic scan that provides important urological information, specifically the filling and releasing of the bladder. This information can help diagnose urological issues in children. However, this procedure requires catheterization, which is understood to be a painful and anxiety-provoking procedure. This study will test the effectiveness of VR as a non-pharmaceutical intervention to relieve pain and anxiety in pediatric patients undergoing VCUGs.

Condition or Disease Intervention/Treatment Phase
  • Device: Oculus Go VR
N/A

Detailed Description

Background: VCUGs are genitourinary diagnostic scans that provide valuable medical information for pediatric patients with urological issues. However, these scans require catheterization, which can be anxiety-provoking, painful, and in some cases traumatic. Previous studies have assessed the use of pharmacological agents to address pain and anxiety during these procedures, but few studies exist examining non-pharmacological interventions in a methodologically rigorous way. As pharmacological interventions are associated with numerous side effects, and may not be appropriate for all pediatric patients, effective non-pharmacological interventions are needed for patients undergoing VCUGs.

Aims: This study aims to determine the effectiveness of virtual reality (VR) in reducing pain and anxiety among children undergoing VCUGs at CHLA. This study will also assess patient, parent, and provider satisfaction with VR, and ease of completing VCUGs using VR vs. the standard of care.

Study Population: CHLA patients aged 5-21 years receiving VCUGs at CHLA. Methods: A stratified randomization scheme will be used to assign patients aged 5-21 undergoing VCUG scans to receive the standard of care (i.e. caregiver presence in the room and Child Life Specialists in the room if desired), or the standard of care plus VR. Individuals assigned to the VR arm will be fitted with a Samsung head-tracking system, and will play an AppliedVR game prior to and during catheterization. Standardized questionnaires will be administered to patients and caregivers before and after the procedure to measure pain and anxiety. Satisfaction questionnaires will be administered post-procedure.

Significance: VR is a non-invasive intervention that, if effective, could become part of a standard protocol to reduce pain and anxiety among children undergoing VCUGs. As there is a dearth of knowledge regarding non-pharmacologic interventions for children receiving VCUGs, this study will provide a foundation to inform future research on VR use among pediatric urology patients.

See 'References' for Brief Summary References

Study Design

Study Type:
Interventional
Anticipated Enrollment :
410 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
The Effectiveness of Virtual Reality (VR) to Reduce Pain and Anxiety During Genitourinary (GU) Scans
Actual Study Start Date :
Feb 15, 2020
Anticipated Primary Completion Date :
Dec 31, 2021
Anticipated Study Completion Date :
Dec 31, 2021

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Standard of Care (No VR) Randomization

Patients will receive standard of care during catheterization, which includes caregiver presence in the room and Child Life Specialists in the room, if desired, and does not include virtual reality.

Experimental: VR Randomization

Patients will receive virtual reality in addition to standard of care.

Device: Oculus Go VR
virtual reality headset

Outcome Measures

Primary Outcome Measures

  1. Change in Pain during VCUG - Pain Visual Analog Scale [Will be administered to participants approximately 20 minutes before the start of the VCUG, and within 15 minutes following the end of the VCUG.]

    Participant levels of pain will be assessed using the Pain Visual Analog Scale (min. score = 0; max. score = 100. Higher score = higher pain)

Secondary Outcome Measures

  1. Change in Pain during VCUG - Faces Pain Scale-Revised [Will be administered to participants approximately 20 minutes before the start of the VCUG, and within 15 minutes following the end of the VCUG.]

    Participant levels of pain will be assessed using the Faces Pain Scale-Revised (min. score = 0; max. score = 10. Higher score = higher pain)

  2. Change in Pain during VCUG - Colored Analog Scale [Will be administered to participants approximately 20 minutes before the start of the VCUG, and within 15 minutes following the end of the VCUG.]

    Participant levels of pain will be assessed using the Colored Analog Scale (min. score = 0; max. score = 10. Higher score = higher pain)

  3. Change in Anxiety during VCUG - Procedural Anxiety Visual Analog Scale [Will be administered to participants approximately 20 minutes before the start of the VCUG, and within 15 minutes following the end of the VCUG.]

    Participant levels of anxiety will be assessed using the Procedural Anxiety Visual Analog Scale (min. score = 0; max. score = 10. Higher score = higher anxiety)

  4. Change in Anxiety during VCUG - Facial Affective Scale [Will be administered to participants approximately 20 minutes before the start of the VCUG, and within 15 minutes following the end of the VCUG.]

    Participant levels of anxiety will be assessed using the Facial Affective Scale (min. score = 0; max. score = 1. Higher score = higher anxiety)

  5. Baseline Anxiety before VCUG - Anxiety Sensitivity Index [Will be administered to participants approximately 20 minutes before the start of the VCUG.]

    Participant baseline anxiety will be assessed using the Anxiety Sensitivity Index, a 16-item questionnaire (min. score = 0; max. score = 64. Higher score = higher anxiety sensitivity; i.e. higher dispositional tendency to fear the somatic and cognitive symptoms of anxiety due to a belief that these symptoms may be dangerous or harmful).

  6. Satisfaction with VR [Questionnaires will be administered to participants within 15 minutes following the end of the VCUG.]

    Participant satisfaction with VR assessed using a 10-item satisfaction survey (min. score = 0; max. score = 50. Higher score = higher satisfaction).

Eligibility Criteria

Criteria

Ages Eligible for Study:
5 Years to 21 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion criteria for children:
  1. Children who are 5-21 years old

  2. Children who are English or Spanish speaking.

  3. Children undergoing a VCUG at CHLA.

  4. Only children who are in the normal range of development will be recruited for this study. This will be assessed by report from the parents. The rationale for excluding patients with developmental delay is that due to their cognitive impairments, such children react to the stressors of medical procedures differently than do children without such developmental delay. It is unclear how such children would use the interventions included in this study, and it is likely that their responses on baseline and outcome measures will differ from children of normal developmental parameters.

Inclusion criteria for caregivers (no age limits):
  1. Have a child who is undergoing a VCUG at CHLA.

  2. Caregiver is present during the child's VCUG.

  3. Caregiver is English or Spanish speaking.

  4. Caregiver is 18 years old or older.

Inclusion criteria for healthcare providers (no age limits):
  1. Provider is 18 years old or older

  2. Provider is a CHLA employee.

  3. Provider may participate if he/she witnessed and/or administered the medical procedure.

Exclusion Criteria:
  1. Child is currently taking pain medication or anxiolytic medication, including midazolam

  2. Child has a psychiatric disorder (i.e. anxiety, psychotic, thought disorder), organic brain syndrome, intellectual disability, Autism Spectrum Disorder, or other known cognitive/neurological disorder

  3. Child has visual, auditory, or tactile deficit that would interfere with the ability to complete the experimental tasks

  4. Child has a history of seizure disorder

  5. Child is currently sick with flu-like symptoms or experiencing a headache or earache

  6. Child has known or suspected motion sickness

  7. Child catheterizes regularly or has an insensate urethra

  8. Languages other than English and Spanish will be excluded given that the proposed measures have not been standardized for use in other languages.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Children's Hospital Los Angeles Los Angeles California United States 90027
2 Children's Hospital Los Angeles Los Angeles California United States 90027

Sponsors and Collaborators

  • Children's Hospital Los Angeles
  • National Association of Theater Owners

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Andy Y. Chang, Attending Physician; Vice Chief, Division of Pediatric Urology, Children's Hospital Los Angeles
ClinicalTrials.gov Identifier:
NCT04251988
Other Study ID Numbers:
  • ChildrenHLA-19-00403
First Posted:
Feb 5, 2020
Last Update Posted:
Jul 15, 2020
Last Verified:
Feb 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Andy Y. Chang, Attending Physician; Vice Chief, Division of Pediatric Urology, Children's Hospital Los Angeles
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 15, 2020